Curis

Curis, Aurigene collaborate for immuno-oncology and precision oncology targets

Thursday, January 22, 2015 12:14 PM

Curis, a Lexington, Mass.-based biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, and Aurigene Discovery Technologies, a Bangalore, India-based, specialized, discovery stage biotechnology company developing novel therapies to treat cancer and inflammatory diseases, have entered into an exclusive collaboration agreement focused on immuno-oncology and selected precision oncology targets.

More... »


Curis licensed IAP inhibitor GDC-0917 from Genentech

Wednesday, November 28, 2012 01:54 PM

Curis, a Lexington, Mass.-based drug development company focused on targeted small molecule drug candidates for cancer treatment, has licensed from San Francisco-based Genentech, a member of the Roche Group, exclusive worldwide rights for the development and commercialization of GDC-0917, a small molecule that is designed to promote cancer cell death by antagonizing inhibitor of apoptosis (IAP) proteins.

More... »


Positive results for Curis phase II trial

Tuesday, March 29, 2011 12:46 PM

Curis, a drug development company focusing on next-generation targeted small molecule drug candidates for cancer treatment, announced a positive outcome from a pivotal phase II clinical trial conducted by Roche and Genentech, Curis' collaborator and a wholly-owned member of the Roche Group, of GDC-0449, a first-in-class hedgehog pathway inhibitor, in patients with advanced basal cell carcinoma (BCC).

More... »

CenterWatch Data Library
CWWeekly

January 19

Roche takes $1B majority stake in Foundation Medicine to use genomic testing to personalize oncology treatments

BRANY launches software, iPad app to streamline protocol creation for investigator-initiated trials

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January

All eyes on EMA’s adaptive licensing pilot
Sponsors could offer innovative drugs to patients 8 years sooner

Ice Bucket Challenge a boon for ALS research
Donations soar, but phenomenon difficult to replicate

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs